T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028 ...

Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial This phase II trial enrolled 225 evaluable ...

ATA3219 Demonstrates Complete CD19-Specific B-Cell Depletion Against Systemic Lupus Erythematosus and Multiple Sclerosis Patient Peripheral Blood Mononuclear Cells ATA3219 Induces Lower Levels of ...

The Malaghan Institute of Medical Research in collaboration with Wellington Zhaotai Therapies Limited today announced results of its phase 1 dose escalation trial of a new third generation anti-CD19 ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — CD19 chimeric antigen receptor T-cell therapy led to remission, or ceased disease progression, over ...

A small study suggests the use of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with mantle cell lymphoma (MCL) with secondary central nervous system (CNS) involvement is safe ...

The press release below was prepared by the American Association for Cancer Research. View the original here. Next-generation sequencing for minimal residual disease was highly sensitive and more ...

Credit: Getty Images. CABA-201 is a 4-1BB-containing fully human CD19-CAR T cell therapy. The Food and Drug Administration (FDA) has granted Fast Track designation to CABA-201 for the treatment of ...

Among recent advances in cancer treatment, it’s hard to think of something with the sheer reach and impact of immunotherapy, a new but rapidly developing field which seeks to leverage the immune ...

Bristol Myers (BMY) “announced that the FDA has granted approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric ...